Finance

Lists
Why is NAUT down 2,30%?
Dive Deeper
NAUT:NASDAQ
Nautilus Biotechnology Inc
2,12 US$
-2,30%
(-0,050) 1D
2,16 US$
+1,82% (+0,039)
After hours
Closed: 20 ნოე, 16:00:03 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAUT...
Open
2,12 US$
High
2,17 US$
Low
1,90 US$
Mkt. cap
270,03 მლნ.
Avg. vol.
8,31 მლნ.
Volume
6,26 მლნ.
52-wk high
4,31 US$
52-wk low
0,84 US$
EPS
-0,46 US$
Beta
0,66
Shares outstanding
127,37 მლნ.
No. of employees
128
Open
2,12 US$
High
2,17 US$
Low
1,90 US$
Mkt. cap
270,03 მლნ.
Avg. vol.
8,31 მლნ.
Volume
6,26 მლნ.
52-wk high
4,31 US$
52-wk low
0,84 US$
EPS
-0,46 US$
Beta
0,66
Shares outstanding
127,37 მლნ.
No. of employees
128
News stories
From web sources and news partners
About Nautilus Biotechnology Inc
CEO-
Employees128
Founded2016
Headquartersსიეტლი, ვაშინგტონის შტატი, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Analyst ratings
Based on 3 analysts giving stock ratings to NAUT in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NAUT in the last 3 months.
Highest
Current 2,12 US$
4,00 US$ (+88,68%)
Average
4,00 US$ (+88,68%)
Lowest
4,00 US$ (+88,68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
4,00 US$
+88,7%
10/28/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
4,00 US$
+88,7%
10/27/2026
Unknown Analyst
Leerink Partners
Buy
Initiated
4,00 US$
+88,7%
09/09/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
4,00 US$
+88,7%
07/28/2026
Daniel Brennan
TD Cowen
Buy
Maintained
-
-
04/28/2026
Last report
27 ოქტ. 2026
Fiscal period
Q3 2026
-0,12 US$ / -0,16 US$
+25,00%beat
Revenue / Est. (USD)
234,00 ათ. / 206,25 ათ.
+13,45%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
-
-
190,00 ათ.
234,00 ათ.
Cost of goods sold
-
-
15,00 ათ.
24,00 ათ.
Cost of revenue
-
-
15,00 ათ.
24,00 ათ.
Research and development expenses
9,58 მლნ.
9,71 მლნ.
9,61 მლნ.
10,18 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,85 მლნ.
6,42 მლნ.
6,32 მლნ.
6,77 მლნ.
Operating expense
15,42 მლნ.
16,12 მლნ.
15,94 მლნ.
16,95 მლნ.
Total operating expenses
15,42 მლნ.
16,12 მლნ.
15,95 მლნ.
16,97 მლნ.
Operating income
-15,42 მლნ.
-16,12 მლნ.
-15,76 მლნ.
-16,74 მლნ.
Other non operating income
-145,00 ათ.
-15,00 ათ.
-13,00 ათ.
-72,00 ათ.
EBT including unusual items
-13,78 მლნ.
-14,70 მლნ.
-14,47 მლნ.
-15,64 მლნ.
EBT excluding unusual items
-13,92 მლნ.
-14,70 მლნ.
-14,47 მლნ.
-15,64 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13,78 მლნ.
-14,70 მლნ.
-14,47 მლნ.
-15,64 მლნ.
Net profit margin
-
-
-7 615,26%
-6 682,05%
Earnings per share
-
-
-
-
Interest and investment income
1,65 მლნ.
1,44 მლნ.
1,31 მლნ.
1,17 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,65 მლნ.
1,44 მლნ.
1,31 მლნ.
1,17 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,02 მლნ.
-15,79 მლნ.
-15,49 მლნ.
-16,46 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები